by | Jun 18, 2021 | Publications
Lancet Oncol. 2021 Jun;22(6):801-812. doi: 10.1016/S1470-2045(21)00128-5.ABSTRACTBACKGROUND: In a phase 1b study, intravenous daratumumab plus pomalidomide and dexamethasone induced a very good partial response or better rate of 42% and was well tolerated in patients...
by MM360 Staff | Jun 14, 2021 | Publications
The anti-B-cell maturation antigen BiTE molecule AMG 420 was assessed in patients with relapsed/refractory multiple myeloma.In this first-in-human study, up to 10 cycles of AMG 420 were given (4-week infusions/6-week...
by MM360 Staff | Jun 14, 2021 | Publications
The combination of lenalidomide, bortezomib, and dexamethasone (RVD) is a highly effective and convenient induction regimen for both transplantation-eligible and -ineligible patients with myeloma. Here, we present the largest cohort […]
by MM360 Staff | Jun 14, 2021 | Publications
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management […]
by MM360 Staff | Jun 14, 2021 | Publications
Click here to read the full article @ Annals of oncology : official journal of the European Society for Medical Oncology
by MM360 Staff | Jun 14, 2021 | Publications
Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate that targets aminopeptidases and rapidly and selectively releases alkylating agents into tumor cells. The phase II HORIZON trial evaluated the efficacy of […]
